CoChat

Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer

Open access
Rojas, Luis, Muñiz, Sabrina, Medina, Lidia, Peña, Jose, Acevedo, Francisco, Pinto, Mauricio P., Sanchez, Cesar · 2020 · PLOS ONE

The DOI matches its Crossref record; 21 of the 22 references it cites were found in a registry or an index.

Abstract

PURPOSE: Trastuzumab (TZM) improves survival and the risk of recurrence among patients with early-stage HER2+ breast cancer (BC). TZM treatment can be given intravenously (IV-TZM) or subcutaneously (SC-TZM). Although both methods have similar efficacy and safety, they differ in dosage and administration. Previous studies of cost minimization determined that SC-TZM is associated with lower costs than IV-TZM; however, those studies did not include the costs associated with body weight-based dosage and the treatment of adverse drug reactions (ADRs). METHODS/PATIENTS: We performed a model-based cost-minimization analysis. The analysis included direct and indirect medical costs associated with TZM preparation (adjusted by body weight) and administration and also costs due to severe ADRs and non-medical costs that occurred during the total treatment course (18 cycles). We performed a sensitivity analysis to test the robustness of the results across various TZM costs and patient body weights. RESULTS: The overall cost (in USD) of IV-TZM treatment was $83,309.1 per patient compared with $77,067.7 per patient for SC-TZM. Thus, one year of SC-TZM treatment cost $6,241.4 less per patient than one year of IV-TZM treatment. The sensitivity analysis revealed that the results were mainly driven by the price of each TZM vial and body weight. CONCLUSION: SC-TZM is a cost-saving therapy for Chilean patients with early-stage HER2+ BC. Given their similar efficacy and safety, we suggest the use of SC formulations rather than IV formulations. The use of SC-TZM instead of IV-TZM may have a significant economic impact on public/private healthcare systems.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0227961

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Sensitivity analysis by ADR costs (costs in USD 2017). Abbreviations: Min: minimum; Max: maximum; SC: subcutaneous; IV: intravenous.
Fig 1 Sensitivity analysis by ADR costs (costs in USD 2017). Abbreviations: Min: minimum; Max: maximum; SC: subcutaneous; IV: intravenous.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 1

  1. MINSAL. Guías Clínicas AUGE Cáncer de Mama. MINSAL. 2015;3: 8–12. Available: https://www.minsal.cl/wp-content/uploads/2015/09/GPC-CaMama.pdf

Cited by

See all 27

Metadata

Authors
Rojas, L., Muñiz, S., Medina, L., Peña, J., Acevedo, F., Pinto, M. P., & Sanchez, C.
Affiliations
  • Pontificia Universidad Católica de Chile (CL)
  • Complejo Asistencial Sótero del Río (CL)
Corresponding author
Sanchez, Cesar
Venue
PLOS ONE
Published
2020-02-05
Volume
15
Issue
2
Pages
e0227961
ISSN
1932-6203 (ISSN-L)
OpenAlex
W3005440288
Cited by
23
References
22
Citations by year
2026: 3 · 2025: 1 · 2024: 8 · 2023: 5 · 2022: 4 · 2021: 2
FWCI
2.34
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
trastuzumab, subcutaneous administration, intravenous administration, HER2-positive breast cancer, early breast cancer, cost-minimization analysis, weight-based dosing, adverse drug reactions, drug costs, health care costs, Chilean patients
MeSH terms
Trastuzumab, Breast Neoplasms, Costs and Cost Analysis, Dose-Response Relationship, Drug, Female, Health Resources, Humans, Injections, Subcutaneous, Incidence, Health Care Costs, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Administration, Intravenous

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer. https://app.cochat.ai/papers/10.1371/journal.pone.0227961
The paper
Rojas, L., Muñiz, S., Medina, L., Peña, J., Acevedo, F., Pinto, M. P., & Sanchez, C. (2020). Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer. PLOS ONE. https://doi.org/10.1371/journal.pone.0227961

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.